Zhen Su/LinkedIn
May 12, 2025, 04:22
Vivek Subbiah: Big thanks to Zhen Su for sharing impressive data from START001
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a post by Zhen Su, CEO at Marengo Therapeutics, adding:
“Big thanks to the amazing Zhen Su for visiting Nashville and sharing impressive data from – START001 – Invikafusp alfa shows promise as a single agent in PD-1 resistant solid tumors (MSS CRC and PD-1 negative NSCLC), and now, -START002 is advancing Invikafusp in combination with Trodelvy for breast cancer patients (HR+/HER2- and TNBC) Erika Hamilton. Exciting progress—kudos and thrilled to collaborate to help patients with cancer Sarah Cannon Research Institute.”
Quoting Zhen Su‘s post:
“Oncology clinical development is a long journey requires teamwork and strong partnerships. It is truly inspiring to visit the all star team of oncology research at Sarah Cannon Research Institute and learn about their amazing work. We are thrilled to partner both our clinical trials with this dream team!
‘Courage is not about knowing the path, it’s about taking the first step’ – Katie Davis Majors
A special thanks to the warm hospitality by Vivek Subbiah, Erika Hamilton, David R. Spigel, Meredith Sellers Pelster. See you again soon at ASCO.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 12, 2025, 04:22
May 11, 2025, 22:51
May 11, 2025, 18:14
May 11, 2025, 18:05
May 11, 2025, 17:07